Key takeaways
Tremfya (guselkumab) and Humira (adalimumab) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Tremfya is a monoclonal antibody that targets interleukin-23 (IL-23) to reduce inflammation and is specifically approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. On the other hand, Humira is a biologic disease-modifying antirheumatic drug (DMARD) that blocks tumor necrosis factor (TNF) and is approved for a wider range of conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis, among others. Tremfya is typically injected every 8 weeks after initial doses, while Humira is usually injected every other week. Tremfya is only available as a brand-name medication, making it potentially more expensive, whereas Humira has several biosimilars available. Both medications can increase the risk of infections, but Humira also carries warnings for potential risks of certain cancers and heart failure.
